This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fujii, T. Articles by Kage, M. Search for Related Content PubMed PubMed Citation Articles by Fujii, T. Articles by Kage, M.

Expression of HER2 and Estrogen Receptor Depends upon Nuclear Localization of Y-Box Binding Protein-1 in Human Breast Cancers

¹ Center for Innovative Cancer Therapy of the 21st Century Center of Excellence Program for Medical Science; ² Biostatistics Center, Kurume University; ³ Department of Surgery, Kurume University School of Medicine; ⁴ Department of Pathology, Kurume University Hospital, Kurume, Japan; ⁵ National Hospital Organization Kyushu Medical Cancer; ⁶ Department of Pharmaceutical Oncology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan; ⁷ Department of Molecular Biology, University of Occupation and Environmental Health, Kitakyushu, Japan; and ⁸ Department of Genome Biology, Kinki University School of Medicine, Osakasayama, Japan

Requests for reprints: Masayoshi Kage, Department of Pathology, Kurume University Hospital, Kurume 830-0011, Japan. Phone: 81-942-31-7651; Fax: 81-942-31-7651; E-mail: masakage{at}med.kurume-u.ac.jp.

Key Words: YB-1 • ErbB2/HER2 • ER • CXCR4 • breast cancer

In our present study, we examined whether nuclear localization of Y-box binding protein-1 (YB-1) is associated with the expression of epidermal growth factor receptors (EGFR), hormone receptors, and other molecules affecting breast cancer prognosis. The expression of nuclear YB-1, clinicopathologic findings, and molecular markers [EGFR, HER2, estrogen receptor (ER), ERβ, progesterone receptor, chemokine (C-X-C motif) receptor 4 (CXCR4), phosphorylated Akt, and major vault protein/lung resistance protein] were immunohistochemically analyzed. The association of the expression of nuclear YB-1 and the molecular markers was examined in breast cancer cell lines using microarrays, quantitative real-time PCR, and Western blot analyses. Knockdown of YB-1 with siRNA significantly reduced EGFR, HER2, and ER expression in ER-positive, but not ER-negative, breast cancer cell lines. Nuclear YB-1 expression was positively correlated with HER2 (P = 0.0153) and negatively correlated with ER (P = 0.0122) and CXCR4 (P = 0.0166) in human breast cancer clinical specimens but was not correlated with EGFR expression. Nuclear YB-1 expression was an independent prognostic factor for overall (P = 0.0139) and progression-free (P = 0.0280) survival. In conclusion, nuclear YB-1 expression might be essential for the acquisition of malignant characteristics via HER2-Akt–dependent pathways in breast cancer patients. The nuclear localization of YB-1 could be an important therapeutic target against not only multidrug resistance but also tumor growth dependent on HER2 and ER. [Cancer Res 2008;68(5):1504–12]

This article has been cited by other articles:

				C. Lee, J. Dhillon, M. Y.C. Wang, Y. Gao, K. Hu, E. Park, A. Astanehe, M.-C. Hung, P. Eirew, C. J. Eaves, et al. Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice Cancer Res., November 1, 2008; 68(21): 8661 - 8666. [Abstract] [Full Text] [PDF]